17,261 trials
Cancer
Primary: Number of Participants With Best Confirmed Response — 0; 1; 0; 13 Participants
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants
Cancer · Colon Cancer · Colorectal Cancer
Primary: Progression-free Survival (PFS) — 7.7; 9.2; 3.7; 6.4 months
Head and Neck Cancer
Primary: Overall Response Rate at 4 Months — 16 percentage of participants
Hyperinsulinemia · Insulin Resistance · Obesity
Primary: Fasting Insulin — 8.1; 8.0; 6.3 uIU/mL — p=0.181
Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Three-dimensional Conformal Radiation Therapy (3DRT), in Terms of Gy Per Fraction, Combined With Concurrent Chemotherapy — 0; 1 units on…
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 21; 17; 1; 0 Subjects
Influenza
Primary: Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza — 100.4; 86.5; 91.9 hours — p=.05
Meningococcal Disease · Meningococcal Meningitis
Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination — 2.1; 2.16; 2.15; 9.84 Titers — p=<0.05
Stroke
Primary: The Modified Rankin Scale Score — 3.9; 3.4; 4.0; 4.4 units on a scale
Kidney Cancer
Primary: Overall Response Rate (ORR) of Patients Treated at MTD/Phase II Dose Level — 13 percentage of evaluable patients
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Dysphagia
Primary: The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months — 0.8; -0.4 cm/s
Autistic Disorder
Primary: Rate of Recruitment — 2.1; 2.1 months/participant at 1 site
End Stage Renal Disease
Primary: The Percent Change From Baseline in ESA Dose Required to Maintain Hemoglobin in the Target Range, Adjusted for Hgb. — 4.9; 39.8 Percent change — p=<0.05